Implantable Neurostimulation Devices Market Report 2024

This Implantable Neurostimulation Devices market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The implantable neurostimulation devices market size has grown rapidly in recent years. It will grow from $7.83 billion in 2023 to $8.68 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth during the historical period can be attributed to the rising demand for non-pharmacological treatments, the increasing preference for minimally invasive procedures, the expanding geriatric population, a broader range of psychiatric disorders, and the growing incidence of chronic diseases.

The implantable neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The growth during the forecast period can be attributed to the rising prevalence of neurological disorders, an increase in lifestyle-related diseases, growing awareness, a rise in spinal cord injuries, and increasing healthcare expenditure. Key trends expected in the forecast period include advancements in sensing technology, progress in neurostimulation technologies, development of technologically advanced products, the incorporation of closed-loop systems, and the integration of wireless technology.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the implantable neurostimulation device market in the future. Neurological disorders are conditions that impact the structure or function of the nervous system, leading to a range of symptoms such as paralysis, seizures, and cognitive impairments. Factors such as high blood pressure, developmental abnormalities, and trauma or injury contribute to higher detection rates of these disorders. Implantable neurostimulation devices are utilized to modulate nerve activity and alleviate symptoms when other treatments prove ineffective or insufficient. For example, in 2024, the Alzheimer's Association, a US-based non-profit organization, reported that approximately 6.9 million Americans aged 65 and older are living with Alzheimer's disease, with 73% being 75 years or older. This figure is projected to increase to 12.7 million by 2050. Consequently, the rising prevalence of neurological disorders is expected to propel the growth of the implantable neurostimulation device market.

Key players in the implantable neurostimulation devices market are developing advanced technologies, such as spinal cord stimulation (SCS) systems, to address chronic pain conditions. An SCS system is a medical device that uses electrical impulses to modulate nerve activity in the spinal cord, providing pain relief and improving patient quality of life when other treatments fail. For instance, in December 2022, Abbott, a U.S.-based medical device company, received FDA approval for the Eterna spinal cord stimulation (SCS) system. The Eterna SCS is the smallest rechargeable implantable spinal cord stimulator on the market, designed for maximum comfort. It features Abbott's BurstDR stimulation technology, which replicates natural brain firing patterns for enhanced pain relief and is preferred by 87% of patients over traditional tingling stimulation. Eterna requires as few as five recharges annually due to Xtend energy technology and supports full-body MRI scans with TotalScan technology. It is also adaptable to future advancements without replacement. Abbott's mobile app integration allows real-time tracking of battery life and charging status on iPhone devices.

In September 2023, Amber Therapeutics, a UK-based provider of neuromodulation therapies, acquired Bioinduction for an undisclosed amount. This acquisition gives Amber access to valuable hardware, expertise, and manufacturing experience, accelerating the development and commercialization of Amber-UI. Bioinduction is a UK-based manufacturer specializing in implantable neurostimulation devices.

Major companies operating in the implantable neurostimulation devices market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Dignity Health, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., CURE Epilepsy, Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Pain Management NYC, Curonix LLC.

North America was the largest region in the implantable neurostimulation devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the implantable neurostimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Implantable neurostimulation devices are medical devices designed to deliver electrical stimulation to specific areas of the nervous system to treat various neurological and psychological conditions. These devices are surgically implanted into the body to modulate nerve activity, offering a sophisticated approach for managing conditions that may not respond adequately to medication alone, thereby enhancing patients' quality of life.

The primary types of implantable neurostimulation devices include spinal cord stimulation (SCS), gastric electric stimulation (GES), deep brain stimulation (DBS), sacral nerve stimulation (SNS), vagus nerve stimulation (VNS), and others. Spinal cord stimulation (SCS) therapy uses mild electrical currents to block pain signals from reaching the brain, providing effective management for chronic pain conditions. These devices are applied in treating pain management, Parkinson's disease, urinary and fecal incontinence, epilepsy, gastroparesis, and other conditions. They are used by various end-users, including hospitals, clinics, and ambulatory surgical centers.

The implantable neurostimulation devices market research report is one of a series of new reports that provides implantable neurostimulation devices market statistics, including implantable neurostimulation devices industry global market size, regional shares, competitors with a implantable neurostimulation devices market share, detailed implantable neurostimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable neurostimulation devices industry. This implantable neurostimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The implantable neurostimulation devices market consists of sales of responsive neurostimulation systems, peripheral nerve stimulation systems, cerebral spinal fluid shunt systems and electroceutical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.